Comparing the current results to its competitors, Cardio Diagnostics Holdings Inc reported Revenue decrease in the 2 quarter 2026 year on year by -28.29 %, despite the revenue increase by the most of its competitors of 18.87 %, recorded in the same quarter.
Cardio Diagnostics Holdings Inc 's Comment on Competition and Industry Peers
The company operates in the cardiovascular diagnostics market, which is characterized by intense competition from both new entrants and established companies. Competitors often possess longer operating histories and greater financial, technical, research, marketing, sales, distribution, and service resources. These advantages enable competitors to respond more rapidly to market changes, regulatory developments, and emerging trends, conduct more extensive research and development, introduce new technologies more quickly, recruit key personnel, execute broader marketing campaigns, and implement aggressive pricing strategies. The company anticipates the emergence of new competitors and increased competition, which may result in the development of similar or more widely accepted solutions by competitors, potentially reducing the company's market share.
Publicly Traded Peers of Cardio Diagnostics Holdings Inc
Myriad Genetics Inc Share Performance
-24.07%
This Quarter
Myriad Genetics Inc
Profile
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Veracyte Inc's business model revolves around providing genomic diagnostic solutions to enable physicians to make more informed treatment decisions for patients.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Sources:
Cardio Diagnostics Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cardio Diagnostics Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
